The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Long‐term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders
Abstract
We sought to review the long‐term tolerability of tetrabenazine (TBZ) and seek determinants of tolerability in the treatment of hyperkinetic movement disorders. A retrospective chart review was performed on patients treated with TBZ between 1997 and 2004. Efficacy of TBZ was assessed by a 1‐ to 5‐point response scale (1 = marked reduction in abnormal movements, 5 = worsening). All adverse events (AEs) were captured according to their relationship with study drug. A total of 448 patients (42% male) were treated for a variety of hyperkinesias, including tardive dyskinesia (n = 149), dystonia (n = 132), chorea (n = 98), tics (n = 92), and myoclonus (n = 19). The mean age at onset of the movement disorder was 43.0 ± 24.2 years, with TBZ starting at a mean age of 50.0 ± 22.3 years. Patients remained on treatment for a mean of 2.3 ± 3.4 years. An efficacy response rating of 1 or 2 was sustained in the majority of patients between the first and last visit. Common AEs included drowsiness (25.0%), Parkinsonism (15.4%), depression (7.6%), and akathisia (7.6%). Comparison of log‐likelihood ratios revealed that age was a reliable predictor of Parkinsonism (P < 0.0001). TBZ is a safe and effective drug for the long‐term treatment of hyperkinetic movement disorders. © 2006 Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A REVIEW OF GOODNESS OF FIT STATISTICS FOR USE IN THE DEVELOPMENT OF LOGISTIC REGRESSION MODELS1
LEMESHOW, S., & HOSMER, D. W. (1982) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a113284 · Cited by 1,947
Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial
Huntington Study Group (2006) · Neurology · doi:10.1212/01.wnl.0000198586.85250.13 · Cited by 471
Cited by
Anderson, K. E., Stamler, D., Davis, M. D., Factor, S. A., Hauser, R. A., Isojärvi, J., Jarskog, L. F., Jimenez-Shahed, J., Kumar, R., McEvoy, J. P., et al. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30236-5 · Cited by 337
Jankovic, J. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70574-9 · Cited by 332
Self-citationTreatment of hyperkinetic movement disorders
Jankovic, J. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70183-8 · Cited by 252
Self-citationThe Synaptic Vesicle Glycoprotein 2: Structure, Function, and Disease Relevance
Stout, K. A., Dunn, A. R., Hoffman, C., & Miller, G. W. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00351 · Cited by 112
Solmi, M., Pigato, G., Kane, J. M., & Correll, C. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s133205 · Cited by 88
Fasano, A., & Bentivoglio, A. R. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903386292 · Cited by 51
Deciphering Ibogaine’s Matrix Pharmacology: Multiple Transporter Modulation at Serotonin Synapses
Hwu, C., Havel, V., Westergaard, X., Mendieta, A. M., Serrano, I. C., Hwu, J., Walther, D., Lankri, D., Selinger, T. L., He, K., et al. (2025) · doi:10.1101/2025.03.04.641351 · Cited by 7
Metadata
- Authors
- Kenney, C., Hunter, C., & Jankovic, J.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2006-11-28
- Volume
- 22
- Issue
- 2
- Pages
- 193-197
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2053778058
- Cited by
- 187
- References
- 2
- FWCI
- 5.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.